I agree that this site is using cookies. You can find further informations here.
X
Ramchandren, Radhakrishnan
81  results:
Search for persons X
?
1

The iR2 regimen (ibrutinib plus lenalidomide and rituximab)..:

Ramchandren, Radhakrishnan ; Johnson, Peter ; Ghosh, Nilanjan...
eClinicalMedicine.  56 (2023)  - p. 101779 , 2023
Link: https://doi.org/10.1016/..
 
?
2

Editorial: Advances in the treatment of Hodgkin lymphoma:

Mei, Matthew ; Perini, Guilherme ; Ramchandren, Radhakrishnan
Frontiers in Oncology.  13 (2023)  - p. , 2023
Link: https://doi.org/10.3389/..
 
?
3

Quality-of-life analysis of pembrolizumab vs brentuximab ve..:

Zinzani, Pier Luigi ; Ramchandren, Radhakrishnan ; Santoro, Armando...
Blood Advances.  6 (2022)  2 - p. 590-599 , 2022
Link: https://doi.org/10.1182/..
 
?
4

P009: Improved Overall Survival with First-Line Brentuximab..:

Hutchings, Martin ; Ansell, Stephen M. ; Connors, Joseph M....
HemaSphere.  6 (2022)  - p. 4-5 , 2022
Link: https://doi.org/10.1097/..
 
?
5

HL-507 First-Line Brentuximab Vedotin Plus Chemotherapy Imp..:

Straus, David ; Radford, John ; Connors, Joseph...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S350 , 2022
Link: https://doi.org/10.1016/..
 
?
6

CTIM-34. PRELIMINARY SAFETY AND EFFICACY DATA ON TWO PATIEN..:

Iqbal, Madiha ; Tun, Han ; Joffe, Erel...
Neuro-Oncology.  24 (2022)  Supplement_7 - p. vii68-vii69 , 2022
Link: https://doi.org/10.1093/..
 
?
7

Outcomes Among Classical Hodgkin Lymphoma Patients After an..:

Hamid, Muhammad Saad ; Rutherford, Sarah C. ; Jang, Hyejeong...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  7 - p. e435-e442 , 2022
Link: https://doi.org/10.1016/..
 
?
8

Poster: HL-507 First-Line Brentuximab Vedotin Plus Chemothe..:

Straus, David ; Radford, John ; Connors, Joseph...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S161 , 2022
Link: https://doi.org/10.1016/..
 
?
9

Autologous stem cell transplantation after anti-PD-1 therap..:

Merryman, Reid W. ; Redd, Robert A. ; Nishihori, Taiga...
Blood Advances.  5 (2021)  6 - p. 1648-1659 , 2021
Link: https://doi.org/10.1182/..
 
?
10

HL-147: Brentuximab Vedotin with Chemotherapy for Patients ..:

Ramchandren, Radhakrishnan ; Dfugosz-Danecka, Monika ; Connors, Joseph M....
Clinical Lymphoma Myeloma and Leukemia.  21 (2021)  - p. S371 , 2021
Link: https://doi.org/10.1016/..
 
?
11

Fimepinostat (CUDC‐907) in patients with relapsed/refractor..:

Landsburg, Daniel J. ; Barta, Stefan K. ; Ramchandren, Radhakrishnan...
British Journal of Haematology.  195 (2021)  2 - p. 201-209 , 2021
Link: https://doi.org/10.1111/..
 
?
12

Concurrent ibrutinib plus venetoclax in relapsed/refractory..:

Wang, Michael ; Ramchandren, Radhakrishnan ; Chen, Robert...
Journal of Hematology & Oncology.  14 (2021)  1 - p. , 2021
Link: https://doi.org/10.1186/..
 
?
13

Poster: HL-147: Brentuximab Vedotin with Chemotherapy for P..:

Ramchandren, Radhakrishnan ; Długosz-Danecka, Monika ; Connors, Joseph M....
Clinical Lymphoma Myeloma and Leukemia.  21 (2021)  - p. S236 , 2021
Link: https://doi.org/10.1016/..
 
?
14

Urelumab alone or in combination with rituximab in patients..:

Timmerman, John ; Herbaux, Charles ; Ribrag, Vincent...
American Journal of Hematology.  95 (2020)  5 - p. 510-520 , 2020
Link: https://doi.org/10.1002/..
 
?
15

Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphom..:

Carreau, Nicole A. ; Pail, Orrin ; Armand, Philippe...
The Oncologist.  25 (2020)  10 - p. 878-885 , 2020
Link: https://doi.org/10.1634/..
 
1-15